An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)

The Efficacy of Adjuvant Chemotherapy With Capecitabine (Xeloda) Monotherapy in Patients With Colon Cancer Stage III (Duke C) Considering the Histopathology of the Tumour (AXEL)

This observational study will evaluate Xeloda (capecitabine) monotherapy on the effect of disease-free survival in patients with colon cancer stage III (Duke C) after surgical resection. Data will be collected for 3 years.

Inclusion Criteria:

• Adult patients, over the age of 18 years
• Presence of colon adenocarcinoma
• Surgical resection for colon cancer stage III (Duke C)
• Prior adjuvant therapy with Xeloda monotherapy

Exclusion Criteria:

• Contraindications for Xeloda